Skip Nav Destination
Issues
1 September 2012
-
Cover Image
Cover Image
Wright–Giemsa-stained cytospin of early passages of TLBR-2 cells in culture. This cell line derived from an aggressive breast implant–associated T-cell CD30+ALK− anaplastic large cell lymphoma (ALCL) shows typical morphologic features, including enlarged nuclei with frequent mitotic figures, multiple prominent nucleoli, pale cytoplasm with vesiculation, and occasional multinucleated giant cells (original magnification, ×400). Along with TLBR-1 and -3, it represents a new model for breast implant–associated ALCL and is characterized by a near triploid karyotype, specific chemotherapy drug sensitivities, and high expression of several pathway signals including Notch1, survivin, antiapoptotic genes, IL-6 and IL-2 autocrine cytokines, and STAT3, which seem to be associated with the oncogenesis and growth for these unique cancers. For details, see the article by Lechner and colleagues on page 4549 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR New Strategies
CCR Perspectives in Drug Approval
The European Medicines Agency Review of Eribulin for the Treatment of Patients with Locally Advanced or Metastatic Breast Cancer: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use
Elias Pean; Sigrid Klaar; Eva Gil Berglund; Tomas Salmonson; Jeanett Borregaard; Kenneth F. Hofland; Jens Ersbøll; Eric Abadie; Rosa Giuliani; Francesco Pignatti
Statistics in Clinical Cancer Research
Molecular Pathways
Perspective
Reviews
Vascular Endothelial Growth Factor Pathway Polymorphisms as Prognostic and Pharmacogenetic Factors in Cancer: A Systematic Review and Meta-analysis
Lawson Eng; Abul Kalam Azad; Steven Habbous; Vincent Pang; Wei Xu; Anke H. Maitland-van der Zee; Sevtap Savas; Helen J. Mackay; Eitan Amir; Geoffrey Liu
Human Cancer Biology
Chromosome 5q Loss in Colorectal Flat Adenomas
Quirinus J.M. Voorham; Beatriz Carvalho; Angela J. Spiertz; Nicole C.T. van Grieken; Sandra Mongera; Eveline J.A. Rondagh; Mark A. van de Wiel; Ekaterina S. Jordanova; Bauke Ylstra; Martin Kliment; Heike Grabsch; Bjorn J. Rembacken; Tomio Arai; Adriaan P. de Bruïne; Silvia Sanduleanu; Philip Quirke; Chris J.J. Mulder; Manon van Engeland; Gerrit A. Meijer
Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer
Kurtis D. Davies; Anh T. Le; Mariana F. Theodoro; Margaret C. Skokan; Dara L. Aisner; Eamon M. Berge; Luigi M. Terracciano; Federico Cappuzzo; Matteo Incarbone; Massimo Roncalli; Marco Alloisio; Armando Santoro; D. Ross Camidge; Marileila Varella-Garcia; Robert C. Doebele
Cancer Therapy: Preclinical
Dual Targeting of the Cyclin/Rb/E2F and Mitochondrial Pathways in Mantle Cell Lymphoma with the Translation Inhibitor Silvestrol
Lapo Alinari; Courtney J. Prince; Ryan B. Edwards; William H. Towns; Rajeswaran Mani; Amy Lehman; Xiaoli Zhang; David Jarjoura; Li Pan; A. Douglas Kinghorn; Michael R. Grever; Robert A. Baiocchi; David M. Lucas
Targeting Aurora Kinases with Danusertib (PHA-739358) Inhibits Growth of Liver Metastases from Gastroenteropancreatic Neuroendocrine Tumors in an Orthotopic Xenograft Model
Katharina Fraedrich; Jörg Schrader; Harald Ittrich; Gunhild Keller; Artur Gontarewicz; Verena Matzat; Arno Kromminga; Andrea Pace; Jürgen Moll; Michael Bläker; Ansgar W. Lohse; Dieter Hörsch; Tim H. Brümmendorf; Daniel Benten
Dual Targeting of mTOR and Aurora-A Kinase for the Treatment of Uterine Leiomyosarcoma
Kari J. Brewer Savannah; Elizabeth G. Demicco; Kristelle Lusby; Markus PH. Ghadimi; Roman Belousov; Eric Young; Yiqun Zhang; Kai-Lieh Huang; Alexander J. Lazar; Kelly K. Hunt; Raphael E. Pollock; Chad J. Creighton; Matthew L. Anderson; Dina Lev
An In Vivo Immunotherapy Screen of Costimulatory Molecules Identifies Fc-OX40L as a Potent Reagent for the Treatment of Established Murine Gliomas
Katherine A. Murphy; Melissa G. Lechner; Flavia E. Popescu; Jessica Bedi; Stacy A. Decker; Peisheng Hu; Jami R. Erickson; M. Gerard O'Sullivan; Lauryn Swier; Andres M. Salazar; Michael R. Olin; Alan L. Epstein; John R. Ohlfest
Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma
Claire Fabre; Naoya Mimura; Kathryn Bobb; Sun-Young Kong; Güllü Gorgun; Diana Cirstea; Yiguo Hu; Jiro Minami; Hiroto Ohguchi; Jie Zhang; Jeffrey Meshulam; Ruben D. Carrasco; Yu-Tzu Tai; Paul G. Richardson; Teru Hideshima; Kenneth C. Anderson
Imaging, Diagnosis, Prognosis
miRNA Biomarkers in Cyst Fluid Augment the Diagnosis and Management of Pancreatic Cysts
Hanno Matthaei; Dennis Wylie; Maura B. Lloyd; Marco Dal Molin; Jon Kemppainen; Skye C. Mayo; Christopher L. Wolfgang; Richard D. Schulick; Laura Langfield; Bernard F. Andruss; Alex T. Adai; Ralph H. Hruban; Anna E. Szafranska-Schwarzbach; Anirban Maitra
The Use of Quantitative Real-Time Reverse Transcriptase PCR for 5′ and 3′ Portions of ALK Transcripts to Detect ALK Rearrangements in Lung Cancers
Rui Wang; Yunjian Pan; Chenguang Li; Haichuan Hu; Yang Zhang; Hang Li; Xiaoyang Luo; Jie Zhang; Zhaoyuan Fang; Yuan Li; Lei Shen; Hongbin Ji; David Garfield; Yihua Sun; Haiquan Chen
CpG Island Methylator Phenotype–Positive Tumors in the Absence of MLH1 Methylation Constitute a Distinct Subset of Duodenal Adenocarcinomas and Are Associated with Poor Prognosis
Tao Fu; Emmanouil P. Pappou; Angela A. Guzzetta; Jana Jeschke; Ruby Kwak; Pujan Dave; Craig M. Hooker; Richard Morgan; Stephen B. Baylin; Christine A. Iacobuzio-Donahue; Christopher L. Wolfgang; Nita Ahuja
Cancer Therapy: Clinical
Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
Andres Cervantes; Elena Elez; Desamparados Roda; Jeffrey Ecsedy; Teresa Macarulla; Karthik Venkatakrishnan; Susana Roselló; Jordi Andreu; JungAh Jung; Juan Manuel Sanchis-Garcia; Adelaida Piera; Inma Blasco; Laura Maños; José-Alejandro Pérez-Fidalgo; Howard Fingert; Jose Baselga; Josep Tabernero
Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations
E. Claire Dees; Roger B. Cohen; Margaret von Mehren; Thomas E. Stinchcombe; Hua Liu; Karthik Venkatakrishnan; Mark Manfredi; Howard Fingert; Howard A. Burris, III; Jeffrey R. Infante
Phase I Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients
Ezra E.W. Cohen; Kehua Wu; Christine Hartford; Masha Kocherginsky; Kimberly Napoli Eaton; Yuanyuan Zha; Anitha Nallari; Michael L. Maitland; Kammi Fox-Kay; Kristin Moshier; Larry House; Jacqueline Ramirez; Samir D. Undevia; Gini F. Fleming; Thomas F. Gajewski; Mark J. Ratain
Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors
Suzanne Leijen; Mark R. Middleton; Patricia Tresca; Françoise Kraeber-Bodéré; Veronique Dieras; Max E. Scheulen; Avinash Gupta; Vanesa Lopez-Valverde; Zhi-Xin Xu; Ruediger Rueger; Jean J.L. Tessier; Eliezer Shochat; Steve Blotner; Valerie Meresse Naegelen; Jan H.M. Schellens; Wilfried Ernst Erich Eberhardt
First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors
Maria Martinez-Garcia; Udai Banerji; Joan Albanell; Rastilav Bahleda; Saoirse Dolly; Françoise Kraeber-Bodéré; Federico Rojo; Emilie Routier; Ernesto Guarin; Zhi-Xin Xu; Ruediger Rueger; Jean J. L. Tessier; Eliezer Shochat; Steve Blotner; Valerie Meresse Naegelen; Jean-Charles Soria
A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer
Lee S. Rosen; Herbert I. Hurwitz; Michael K. Wong; Jonathan Goldman; David S. Mendelson; William D. Figg; Shawn Spencer; Bonne J. Adams; Delia Alvarez; Ben K. Seon; Charles P. Theuer; Bryan R. Leigh; Michael S. Gordon
A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma
Melissa Alsina; Suzanne Trudel; Richard R. Furman; Peter J. Rosen; Owen A. O'Connor; Raymond L. Comenzo; Alvin Wong; Lori A. Kunkel; Christopher J. Molineaux; Andre Goy
Bone-Related Complications and Quality of Life in Advanced Breast Cancer: Results from a Randomized Phase III Trial of Denosumab versus Zoledronic Acid
Miguel Martin; Richard Bell; Hugues Bourgeois; Adam Brufsky; Ingo Diel; Alexandru Eniu; Lesley Fallowfield; Yasuhiro Fujiwara; Jacek Jassem; Alexander H.G. Paterson; Diana Ritchie; Günther G. Steger; Alison Stopeck; Charles Vogel; Michelle Fan; Qi Jiang; Karen Chung; Roger Dansey; Ada Braun
Letter to the Editor
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.